Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cambrex Makes Senior Appointments | Contract Pharma

What are you searching for?

Sign in
Promotions & Moves

Cambrex Makes Senior Appointments

New roles to further support the company’s CDMO business

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cambrex Corp. has appointed Bruno Biscaro as president, Drug Products, with global responsibility for the company’s drug product business.

Mr. Biscaro has 30 years of experience in pharmaceutical leadership and joins Cambrex from Famar where he was president, North America. Prior to this role, he was President of Accucaps Industries and has also held numerous leadership positions for GlaxoSmithKline including his last mandate as Regional Director, Global Supply Network Program for the North American Supply Executive Team.

Also, Joe Nettleton has been appointed president, Drug Substance, with responsibility for operations at the Charles City, Iowa; Karlskoga, Sweden; Wiesbaden, Germany; and Tallinn, Estonia facilities. Mr. Nettleton previously served as vice president, US Operations and has been with Cambrex for 28 years.

Lastly, Simon Edwards has been appointed president, CDMO Sales & Marketing. He will provide customers with a single point of contact for the company’s CDMO services, as well as drive commercial activity and brand recognition for Cambrex as the leading small molecule company.

“I’m delighted to announce these appointments that underpin our strategy to be the leading small molecule company with the ability to serve customers across the entire drug lifecycle,” commented Shawn Cavanagh, executive vice president and chief operating officer. “Our recent acquisitions of Avista and Halo align with this strategy and leverages our core strengths, while positioning us as a leading global provider of end-to-end integrated services for small molecules. These appointments play a crucial role in Cambrex delivering a wider range of services to new and existing customers.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics